We know that MRD is relevant, what next?

Bijal Shah

It is now widely agreed that minimal residual disease (MRD) is a clinically relevant measure, so how can we now move forward to achieve the widespread utilization of MRD measurement in a meaningful way? This question is explored here, in an interesting discussion with Bijal Shah, MD, of the H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL. Dr Shah raises the topic of what we should now define as complete and partial response rates, and whether we should still be using these terms. He also discusses the subjects of what weight should be given to different mutations, standardization, therapy guidance and impact on transplant. This video was recorded at the 1st International Workshop on Acute Leukemias (iwAL), held in St. Pete Beach, FL.

Share this video